Technology

Evelo Biosciences

$16.65
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.30 (+1.83%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell EVLO and other stocks, options, and ETFs commission-free!

About EVLO

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA. The listed name for EVLO is Evelo Biosciences, Inc. Common Stock.

CEO
Balkrishan Gill
Employees
98
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
647.18M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
249.20K
High Today
$17.57
Low Today
$15.11
Open Price
$15.71
Volume
221.71K
52 Week High
$17.71
52 Week Low
$3.01

Collections

EVLO Earnings

-$0.78
-$0.52
-$0.26
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 11, Pre-Market

You May Also Like

GLADL
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure